Kezar Life Sciences Inc. (NASDAQ:KZR) does about 607.24K shares in volume on a normal day but saw 470274 shares change hands in Friday trading. The company now has a market cap of 449.07M USD. Its current market price is $6.65, marking an increase of 4.89% compared to the previous close of $6.34. The 52 week high reached by this stock is $18.55 whilst the lowest price level in 52 weeks is $4.30. The script in recent trading has seen the stock touch a high of $6.73 and a low of $6.27.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Kezar Life Sciences Inc. (KZR) has a 20-day trading average at $6.77 and the current price is -64.15% off the 52-week high compared with 54.47% distance from its 52-week low. The 50-day simple moving average of the closing price is $6.79 and its 200-day simple moving average is $7.68. If we look at the stock’s price movements over the week, volatility stands at 4.69%, which increases to 4.90% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 48.76 to suggest the stock is neutral.
6 analysts observing the Kezar Life Sciences Inc. (KZR) stock have set the 12-month price targets for the company’s shares at between $14.00 and $21.00. The consensus objective for the share price is $18.00, suggesting that the stock has a potential upside of 63.06% over the period. The median price target is 60.88% away from the current levels at $17.00.
FactSet Research has provided data showing that 6 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 6 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 08, 2021 when Wells Fargo initiated the stock to “Overweight” and issued a price target of $19. Wells Fargo initiated its price target at $30.
The current price level is -1.61%, -2.16%, and -13.75% away from its SMA20, SMA50, and SMA200 respectively, with the KZR price moving above the 50-day SMA on February 17. Kezar Life Sciences Inc. (KZR) stock is up 1.84% over the week and 6.40% over the past month. Its price is -5.54% year-to-date and -56.56% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of -$0.25 above consensus estimates by $0.02.
To reach the target analysts have set, the stock logically needs to grow 63.06 percent from here.
Outstanding shares total 72.15M with insiders holding 20.94% of the shares and institutional holders owning 87.20% of the company’s common stock. The company has a return on equity of -25.50%. The beta has a value of 0.23. Price to book ratio is 1.70.
According to a U.S. Securities and Exchange Commission filing, SPDR S&P Biotech ETF has added its position in Kezar Life Sciences Inc. (KZR) to 3,235,676 shares, mirroring a recent increase by 0.32%. SPDR S&P Biotech ETF added 10416.0 shares of Kezar Life Sciences Inc. common stock bringing its total worth to about $23.2 million at the end of recent close, SEC documents show. SPDR S&P Biotech ETF isn’t the only investment manager who changed stakes and is followed by BB Biotech AG, which sold off -1.92 million shares to end up with 3,000,000 shares worth $21.51 million.
